Zoetis Inc. $ZTS Stock Sold by Boston Trust Walden Corp

Boston Trust Walden Corp lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 63.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,769 shares of the company’s stock after selling 69,618 shares during the period. Boston Trust Walden Corp’s holdings in Zoetis were worth $2,777,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Zoetis during the second quarter valued at approximately $25,000. Dunhill Financial LLC grew its stake in shares of Zoetis by 519.3% in the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after buying an additional 296 shares during the last quarter. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Zoetis in the 1st quarter worth approximately $28,000. Wellington Grp LLC grew its stake in shares of Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after buying an additional 267 shares during the last quarter. Finally, Provenance Wealth Advisors LLC increased its position in Zoetis by 1,866.7% during the 3rd quarter. Provenance Wealth Advisors LLC now owns 531 shares of the company’s stock valued at $37,000 after buying an additional 504 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Adjusted EPS of $1.75 topped the $1.51 consensus, while revenue of $2.39 billion exceeded expectations of $2.30 billion. Zoetis also raised its full-year 2026 profit outlook. Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
• Positive Sentiment: Livestock revenue grew 7% to $797 million, helping offset softness in companion-animal products. Jefferies also raised its price target to $85 from $83. Zoetis: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Investors appear focused on ongoing pressure in the pet-health business: owners are cutting back on veterinary visits, and Zoetis is taking a cautious view of 2027. Competitive pressures and margin headwinds also weigh on the outlook. Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall ZTS Q3 2026 deep dive: Competitive pressures and margin headwinds weigh on outlook
• Negative Sentiment: Despite beating estimates, quarterly revenue declined 1.3% year over year, reinforcing concerns that strength in livestock may not fully offset weaker companion-animal demand. Zoetis reports third-quarter results

Zoetis Stock Performance

ZTS stock opened at $79.50 on Friday. The stock has a market capitalization of $32.85 billion, a PE ratio of 13.52, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67. Zoetis Inc. has a 12-month low of $68.77 and a 12-month high of $132.49. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The stock’s 50 day simple moving average is $75.68 and its 200 day simple moving average is $92.60.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, November 5th. The company reported $1.75 EPS for the quarter, beating the consensus estimate of $1.51 by $0.24. The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The company’s revenue was down 1.3% compared to the same quarter last year. During the same period last year, the business posted $1.70 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.15 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. Zoetis’s dividend payout ratio (DPR) is 34.93%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ZTS shares. UBS Group lifted their price objective on Zoetis from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Tuesday, October 27th. Morgan Stanley reduced their price target on Zoetis from $85.00 to $82.00 and set an “overweight” rating for the company in a report on Thursday, October 29th. Cantor Fitzgerald set a $94.00 price target on Zoetis in a research report on Tuesday, August 25th. Leerink Partners dropped their price target on shares of Zoetis from $95.00 to $80.00 and set a “market perform” rating on the stock in a research note on Monday, July 13th. Finally, BTIG Research dropped coverage on shares of Zoetis in a research report on Friday, October 30th. They set a “buy” rating and a $200.00 price objective on the stock. Eight research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $101.25.

About Zoetis

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish.

The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Zoetis originated as Pfizer’s animal health business and became an independent public company in 2013.